Business
DalCor Pharma licenses a late-stage investigational cardiovascular drug following major discovery by Montreal Heart Institute (MHI) scientists
New company DalCor to sponsor global phase III clinical trial to be led by MHI MONTREAL...
About this update from Criterium Energy Ltd
[{"type":"text","content":"\n\n\nNew company DalCor to sponsor global phase III clinical trial to be led by MHI\n\n\n\nMONTREAL, June 8, 2015 /CNW Telbec/ - DalCor Pharmaceuticals Canada Inc. (DalCor) and the Montreal Heart Institute (MHI) announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine. This program is part of a major effort by DalCor and its backers, who include significant private capital, to bolster the economy of Quebec by investing in the region's health care capabilities.  \n\nThe trial will seek to validate the clinical efficacy of dalcetrapib, an investigational medicine that according to a recently published analysis by the MHI could reduce cardiovascular morbidity and mortality by as much as 39% in patients with a documented recent Acute Coronary Syndrome and with the appropriate genetic profile. This Phase III clinical study will screen more than 30,000 patients across 30 countries in order to identify 5,000 patients having the appropriate genetic profile that is expected to benefit from dalcetrapib. DalCor estimates that $250 million will be required to complete the project. MHI will be retained by DalCor as the lead academic Clinical Research Organization for the Phase III trial.  The trial will be conducted in collaboration with the Montreal Health Innovations Coordinating Centre (MHICC), a division of the MHI, and other international Contract Research Organizations.\n\nCardiovascular disease, including coronary atherosclerosis, is the leading cause of death in the world. Recent results published this past January by MHI researchers led by Drs Jean-Claude Tardif and Marie-Pierre Dubé in Circulation: Cardiovascular Genetics indicated that patients with certain genotypes exhibited a benefit in terms of reduced cardiovascular risk when treated with dalcetrapib as compared to placebo. \"Our Dal-GenE study is prospectively testing dalcetrapib in patients with a documented recent acute coronary syndrome  and a specific genetic profile\", said Dr. Jean-Claude Tardif, Director of the Research Center at MHI, Professor of Medicine at the University of Montreal and holder of the Canada Research Chair in personalized medicine. Typically, precision therapy results in better patient outcomes and pote...